Search
Olmutinib
go.drugbank.com/drugs/DB13164InvestigationalOlmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim. … Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016.
Pagoclone
go.drugbank.com/drugs/DB04903InvestigationalPagoclone is an anxiolytic drug from the cyclopyrrolone family, which is related to other more well known drugs such as the sleeping medication zopiclone. … It is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures
Trestolone
go.drugbank.com/drugs/DB05830InvestigationalTrestolone (7α-methyl-19-nortestosterone) is a synthetic androgen developed by the Population Council as a potential candidate drug for use in hormonal male contraceptive methods.
Ligelizumab
go.drugbank.com/drugs/DB11856InvestigationalSimilar in mechanism to [omalizumab], another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer … autoantibodies against IgE receptors, and sometimes against IgE itself, are thought to exist in 30-40% of patients,[A242362,A242367] and the efficacy anti-IgE antibody therapy in the treatment of CSU has
Creatine
go.drugbank.com/drugs/DB00148ApprovedInvestigationalNutraceuticalIn muscle tissue, creatine generally occurs as phosphocreatine. Creatine is excreted as creatinine in the urine.
Cianidanol
go.drugbank.com/drugs/DB14086ApprovedInvestigationalWithdrawnAn antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.
Darbepoetin alfa
go.drugbank.com/drugs/DB00012ApprovedInvestigationalHuman erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Reposal
go.drugbank.com/drugs/DB13805ExperimentalReposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and anticonvulsant properties. It was used primarily in the treatment of insomnia.
Trilostane
go.drugbank.com/drugs/DB01108ApprovedVet approvedWithdrawnIt was withdrawn from the United States market in April 1994.
AS-8112
go.drugbank.com/drugs/DB09207ExperimentalIt has been shown to exert potent antiemetic effects in animal studies and has been investigated for potential medical use. … AS-8112 is a synthetic compound that acts as a selective antagonist at the dopamine receptor subtypes D2 and D3, and the serotonin receptor 5-HT3.